Arovella Therapeutics announced the resignation of CEO Michael Baker, alongside a shareholder notice seeking the removal of two directors. David Williams has been appointed Chairman of the Board. The news points to governance instability and activist pressure, but no operational or financial figures were provided.
Arovella Therapeutics announced the resignation of CEO Michael Baker, alongside a shareholder notice seeking the removal of two directors. David Williams has been appointed Chairman of the Board. The news points to governance instability and activist pressure, but no operational or financial figures were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.15
